Kaleido Biosciences Company Description

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies.

The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.

It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases.

The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen.

Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Kaleido Biosciences, Inc.

Country	United States
Founded	2015
Industry	Biotechnology
Sector	Healthcare
Employees	76

Contact Details

Address: 65 Hayden Avenue Lexington, Delaware 02421 United States
Phone	617 674 9000
Website	kaleido.com

Stock Details

Ticker Symbol	KLDO
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US4833471000
SIC Code	2836

Key Executives

Name	Position
Kimberly Hocknell	Senior Vice President of Technical Operations
Dr. Mark A. Wingertzahn Ph.D.	Senior Vice President of Research & Development and Head of Development